Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 18 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

6%

1 trials in Phase 3/4

Results Transparency

33%

2 of 6 completed with results

Key Signals

2 with results100% success

Data Visualizations

Phase Distribution

15Total
Not Applicable (8)
P 1 (3)
P 2 (3)
P 4 (1)

Trial Status

Recruiting6
Completed6
Not Yet Recruiting3
Unknown2
Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 6 completed trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT07732634Phase 2Not Yet Recruiting

RiMO-HNC-NEO1: Phase 2 Study of RiMO-301 and Hypofractionated Radiotherapy With Pembrolizumab for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer

NCT04722523Phase 1Recruiting

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

NCT07674706Not ApplicableNot Yet Recruiting

Evaluating the Optimal Timing of Acupuncture for Managing Chemoradiation-induced Xerostomia in Patients With Head and Neck Cancers

NCT05420948Phase 2Recruiting

A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

NCT06722508Not ApplicableRecruitingPrimary

Exercise and Nutritional Prehabilitation for Head and Neck Cancer Patients

NCT04673981Not ApplicableRecruitingPrimary

Neurosensorial Disorder and Pain in Oral Cavity and Oropharynx Cancer Traited Patients (OCAPA)

NCT04750434CompletedPrimary

PET MRI as a Staging Tool for Head and Neck Cancer

NCT06395805RecruitingPrimary

Evaluation of Quality of Life and Self-assurance and Social Support Earned for Non-cellular Head Cancer

NCT05472506Phase 1Withdrawn

Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer

NCT05946577Not Yet RecruitingPrimary

Association Between Tinnitus and Hearing Loss in Locally Advanced Head and Neck Cancer Treated by Radiotherapy Alone or With Chemotherapy: a Prospective and Multicenter Study

NCT05549414Not ApplicableRecruiting

Pivotal Study of Proton Radiotherapy Treatments Using Fixed Beam Chair-Based Delivery System

NCT02714920Not ApplicableCompletedPrimary

DNA Repair Enzyme Signature in Head and Neck Cancer (CHEMRAD)

NCT02738268Not ApplicableCompletedPrimary

Laser Therapy for the Prevention of Radiodermatitis in Head and Neck Patients

NCT04905030Not ApplicableUnknown

Education, Immigration and HPV Vaccination: an Informational Randomized Trial

NCT04261179Phase 4UnknownPrimary

Study Comparing Lymphoseek® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer

NCT01194466Not ApplicableCompletedPrimary

Transcutaneous Electrical Nerve Stimulation (TENS) and Head and Neck Cancer Pain (HNC) (TENS & HNC)

NCT00318890Phase 1Completed

Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck

NCT00798655Phase 2Completed

Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer

Showing all 18 trials

Research Network

Activity Timeline